https://scholars.lib.ntu.edu.tw/handle/123456789/194574
標題: | 以樹突細胞為主的免疫療法治療在小鼠的殘餘血癌疾病模式(1/2) | 作者: | 周獻堂 | 公開日期: | 2005 | 出版社: | 臺北市:國立臺灣大學醫學院小兒科 | 摘要: | 我們的初步資料顯示﹐腫瘤抗原-pulsed 的樹狀細胞能夠引起專一性及保護性的抗血 癌效果﹐並且能夠明顯的延長有植入小鼠RL male 1 血癌細胞株的BALB/c 小鼠的存活 時間。根據以上研究資料﹐我們提出此研究計劃來測試以樹狀細胞為主的免疫療法﹐ 用來作為臨床化學療法後的殘餘腫瘤的輔助治療﹐以期避免腫瘤的再復發。 在今年﹐我們已建立小鼠血癌疾病模式(圖一)﹐並藉由化學治療來治療已建立起 明顯的血癌疾病﹐使其達到緩解(圖二)﹐並觀察其會復發與否(圖三)﹐以研究由 骨髓細胞所衍生的樹狀細胞所引發的腫瘤專一性免疫反應。我們將藉由檢定各種體外 的免疫反應和體內的抗殘餘血癌效果﹐以評估各種的pulsed(TA 或TA/adeno-IL12)及非 pulsed 的樹狀細胞的效用﹐及最佳的疫苗施打方案。 Our preliminary results have demonstrated that vaccination with tumor antigen(TA)-pulsed DCs could induce a specific protective anti-leukemia effect and significantly prolonged survival of BALB/c mice that were challenged with murine RL male 1 leukemia. Based on our preliminary data, we propose this study to test that the capacity of DC-based immunization may have clinical implications as the adjuvant treatment of residual leukemia after the traditional induction chemotherapy to prevent the recurrence of the disease. In this year, we have established the murine leukemia model (Figure 1) and by initial chemotherapy for the established frank leukemia status to induce remission (Figure 2), monitor relapse or not(Figure 3) and investigate the effect of BM-derived DCs in inducing tumor-specific immune response. We will evaluate the efficiency of various pulsed (TA or TA/adeno-IL12) or unpulsed-DCs by both in vitro immune response assays and in vivo antiresidual leukemia effect. We will also elucidate the novel optimal immunization schedule for inducing the competent anti-residual tumor immune response. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/22913 | 其他識別: | 932314B002133 | Rights: | 國立臺灣大學醫學院小兒科 |
顯示於: | 醫學系 |
檔案 | 描述 | 大小 | 格式 | |
---|---|---|---|---|
932314B002133.pdf | 325.95 kB | Adobe PDF | 檢視/開啟 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。